研生生醫參加北美生技展示獨特生物技術研發抗體開發平台及新藥開發進展
廠商名稱:研生生醫股份有限公司
發佈日期:2022-07-28
攤位號碼:R127
SAN DIEGO — AcadeMab participates in the 2022 BIO International Convention, the largest biotech industry exhibition in the world, and expands its business diligently.
The BIO International Convention is the world's largest annual biotech event, held in major cities in the United States. Around 1,140 companies opened their booths in the BIO USA 2022, with more than 15,000 people to visit from all over the world. The conference is the first to be held with in-person participation in three years due to the COVID-19 pandemic. This year's convention was held in San Diego, USA from June 13th to 16th. AcadeMab participated in an exhibition group jointly consisting of Taiwanese officials and industries and exhibited at the Taiwan Pavilion to introduce its new biological entities and the unique antibody developmentplatform for biotech research and development.
Since its establishment in 2020, AcadeMab has developed its own biological pipelines and technology platforms for antibody discovery and development. It has accumulated experience in novel antibodies development and seeks for potential partners for R&D collaboration or in- & out-licensing business. Its leading pipeline, AM-928, is moving forward in a fast path and will enter clinical stage in early 2023. Other than the pipeline development, reliable and high-qualityantibody discovery services to customers could also be provided with its unique technology platforms, including human scFv phage display and single B cell technology.
Through the intensive exposureand connection during this exhibition, AcadeMab will continue to contact many potential partners, show our in-depth knowledge and advantages, and establish global business opportunities.
更多參展商新聞稿
- 瑞士Levitronix第三方研究報告:比較不同泵系統對蛋白質施加的機械剪切應力的研究 瑞士商力威磁浮技術有限公司 台灣分公司 / 2022-08-01
- 瑞士Levitronix第三方研究報告:比較不同泵系統對CHO細胞施加的機械剪切應力的研究 瑞士商力威磁浮技術有限公司 台灣分公司 / 2022-08-01
- 瑞士Levitronix第三方研究報告:不同泵系統的顆粒物脫落程度比較與評估 瑞士商力威磁浮技術有限公司 台灣分公司 / 2022-08-01
- 2022亞洲生技大展盛大開幕,微體生醫展出最新亮眼成績 微體生物醫學股份有限公司 / 2022-07-30
- GARAOTUS提供MedGenome基因組分析整體解決方案,並提升其89%基因分析效能 GARAOTUS (SYSTEX GROUP) / 2022-07-30
- FDA批准國鼎生技申請新冠肺炎新藥之 Pre-EUA Meeting Request會議請求 國鼎生物科技股份有限公司 / 2022-07-30
- Antroquinonol (HOCENA), 致力研發創新, 突破,增進生活品質理想藥物 國鼎生物科技股份有限公司 / 2022-07-30
- 產研攜手共創AI生醫加速器-國衛院與華碩集團合作簽約儀式 財團法人國家衛生研究院 / 2022-07-29
- 義大利攜7大廠商第三度參展BIO ASIA亞洲生技大會 義大利經濟貿易文化推廣辦事處貿易組 / 2022-07-29
- 蔡英文:2021國內生技營業額破七千億台幣! 盼展會加持串接價值鏈 環球生技多媒體股份有限公司 / 2022-07-28
- 串接亞洲生技價值鏈 2022亞洲生技大會盛大回歸! 環球生技多媒體股份有限公司 / 2022-07-28
- 研生生醫開發出對抗COVID-19 Omicron 變異株的高度中和效力治療性抗體 研生生醫股份有限公司 / 2022-07-28
- 新冠有解?研生發現抗病毒變異株人類抗體 研生生醫股份有限公司 / 2022-07-28
- IPO也要話題行銷 台灣健康產業協會 / 2022-07-28
- 艾明康生技公司開發居家視力檢測「艾明康守護孩子視力方案」,別讓「假性近視」變成真近視 艾明康生技股份有限公司 / 2022-07-28
- 2022 亞洲生技大展, 中山醫學大學專家與您有約 中山醫學大學 / 2022-07-27
- 2022「台北生技獎」揭曉 倍利科技獲「跨域卓越獎」殊榮 倍利科技股份有限公司 / 2022-07-27
- 逸達生技 前列腺癌新劑型新藥 CAMCEVI 42毫克正式於美國上市 逸達生物科技股份有限公司 / 2022-07-27
- 逸達前列腺癌新劑型新藥 CAMCEVI 通過歐盟EMA新藥上市許可 逸達生物科技股份有限公司 / 2022-07-27
- 霖揚深化胜肽與重組蛋白藥物CDMO服務 霖揚生技製藥股份有限公司 / 2022-07-27